Wendy future of retail top

Nicole Kidman partners with Seratopical by SeraLabs

Print Friendly, PDF & Email

LOS ANGELES — CURE Pharmaceutical Holdings, the wholly owned subsidiary The SeraLabs, Inc., has teamed with Oscar, Golden Globe and Emmy Award-winning Nicole Kidman as the brand’s first-ever strategic business partner and global brand ambassador for their topical products. In addition to being the face of the brand, Kidman will play an integral role in the strategic direction of product development and messaging.

Nicole Kidman

“We could not be more excited by Nicole’s decision to join our team,” says Nancy Duitch, SeraLabs CEO and CURE Pharmaceutical chief strategic officer. “We wanted to work with someone who genuinely cares about growing the business as much as we do. A person just looking to lend their name was never going to work for us. She is savvy, forward thinking and embodies our brand values.”

Kidman became a proponent of the benefits of topical CBD when she experimented with it on an ankle injury last summer. She will bring her vast experience of the beauty sector to help SeraLabs boost its multi-channel distribution efforts and sales for its anti-aging skincare line, Seratopical and topical ultra-hydrating and pain relief body creams and serums. The deal includes nine current SeraLabs topical products with an additional three products set to launch in 2021 where Kidman will be key in development.  

“The partnership with SeraLabs was an easy decision for me,” states Kidman, SeraLabs Strategic Partner and Global Brand Ambassador. “With my injury last year, I experienced the benefit of CBD wellness products firsthand. I believe these products are a vital solution in health and wellness and Nancy and SeraLabs are a company I believe in.  Joining them in this partnership is something I am very excited about.”

Seratopical line

SeraLabs was founded in 2018 and is a global leader in the health, wellness, and beauty sectors. CURE Pharmaceutical Holdings which acquired SeraLabs in 2020 is focused on the innovation of pharmaceutical technology, wellness products and drug delivery. “The growth and global interest of our newest acquisition SeraLabs has been tremendous over the past few months,” said CURE Pharmaceutical CEO, Rob Davidson. “Nicole will undoubtedly help SeraLabs reach more consumers than ever before and grow our revenue exponentially over the next few years.”


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21